Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company enrolled its first patient in a North American Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247, on January 4, 2006. The trial will be performed at thirty-four centers across North America , including twenty-nine centers in the United States and ...
Darmstadt, Germany (ots/PRNewswire) - Merck KGaA today announced an organizational change in the Merck Generics Group (MGG), naming J. Melville ("Mel") Engle to the post of MGG Regional Director, North America. Mr. Engle will retain his current position of President and Chief Executive Officer of Napa, CA-based DEY, L.P., a Merck subsidiary. (Photo: ...
Ludwig-Maximilians-University of Munich
Munich, Germany (ots/PRNewswire) - A new study published today in the European Archives of Psychiatry and Clinical Neuroscience demonstrates that quetiapine (SEROQUEL) and risperidone (RISPERDAL) have equivalent efficacy in the treatment of patients with schizophrenia exhibiting predominately negative symptoms, ...
Alderley Park, England (ots/PRNewswire) - - Filing Seeks Approval of SEROQUEL as a Monotherapy Treatment for Bipolar Depression AstraZeneca today announced submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) to seek approval for a new indication for SEROQUEL(R) (quetiapine fumarate) for the treatment of ...
Lyon, France (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has entered into an agreement with BD (Becton, Dickinson and Company) (NYSE: BDX) to license the Micro-Delivery technology of BD Medical-Pharmaceutical Systems for use in the administration of sanofi pasteur's human vaccine products. ...
Basel, Switzerland (ots/PRNewswire) - - Power of "FUZEON effect" Provides Much Needed Hope for HIV Patients Facing Treatment Failure Exciting interim data presented at the annual ICAAC(i) conference show that adding FUZEON (enfuvirtide) to the investigational boosted protease inhibitor (PI), TMC114/r, more than doubles the proportion of patients reaching ...
Madrid (ots/PRNewswire) - - IDMC Recommends Adoption of 24hr Dosing in Pivotal Trial PharmaMar today announces that the independent data monitoring committee (IDMC) for the pivotal trial of YONDELIS(R) in Soft Tissue Sarcoma (STS) has reviewed data from a pre-planned interim analysis of the primary end-point, Time to Progression (TTP), which indicate that ...
Lyon, France (ots/PRNewswire) - - Data Show That the Vaccine is Safe, Demonstrates Immunogenicity and Provides Future Direction for Development Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that preliminary results of clinical trials fielded in France of an adjuvanted ...
Alderley Park, England (ots/PRNewswire) - AstraZeneca announced today that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for ZD6474 (ZACTIMA(TM)) for the treatment of patients with medullary thyroid cancer in the European Union (EU). ...
Madrid (ots/PRNewswire) - PharmaMar today announces the results of the Aplidin(R) Phase II trial which were presented at the American Society of Hematology 47th Annual Meeting in Atlanta, Georgia, USA, on Sunday 11 December. Aplidin reached its objective of overall response rate established in the first stage of ...
Indianapolis (ots/PRNewswire) - Data presented today offer evidence that an investigational targeted therapy may be useful in treating patients with the most common form of non-Hodgkin's lymphoma (NHL). The five-year survival rate of U.S. patients with NHL is only 59 percent with standard therapies, according to the Lymphoma Research Foundation. Diffuse large ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today nine month interim safety and efficacy data obtained from its 24 week Phase III psoriasis trial and 12 week extension for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an ...
Macclesfield, England (ots/PRNewswire) - 'New Data Outcomes in Early Breast Cancer: Improving the Odds for Survival' News that could change the landscape for hormonal treatments in postmenopausal women Room: 0001B, River Level, Henry B. Gonzalez Convention Center, ...
Cephalon, Inc.; Zeneus Holdings Limited
Frazer, Pennsylvania. and Oxford, England (ots/PRNewswire) - - Transaction Opens European Oncology Market for Cephalon; Creates Additional Direct Presence in Europe's Five Major Markets Cephalon, Inc. (Nasdaq: CEPH) and Zeneus Holdings Limited announced today that the companies have signed a definitive purchase agreement under which Cephalon, Inc. will acquire all of the outstanding share capital of Zeneus ...
Research Triangle Park, North Carolina (ots/PRNewswire) - - Now has clinical development offices in eight Asia countries Quintiles Transnational Corp. today announced the extension of its Asia operations with the opening of an office in Hanoi, Vietnam. "Vietnam is an increasingly important market in the region, with its population of 80 million, a strong educational system and a robust healthcare industry," ...
Zurich (ots) - cablecom has secured an order in Geneva worth CHF 20 million that involves modernization of three cable networks. For 25,000 households in Onex, Lancy and Carouge, the project will provide access to cablecom's triple play service, featuring digital television, broadband Internet and digital telephony. Under this multi-year contract, the three municipalities have commissioned cablecom to modernize ...
Alderley Park, England, November 23 (ots/PRNewswire) - - First patient enrolled into double-blind, randomised, placebo-controlled study to investigate overall survival in a broad NSCLC population AstraZeneca (NYSE: AZN) announced today the start of recruitment into a pivotal Phase II/III study of the ...
Boca Raton, Florida, November 22 (ots/PRNewswire) - PharmaMar announces the presentation of data from two research projects at the 11th Annual CTOS (Connective Tissue Oncology Society) Meeting, which took place in Florida, USA, from November 19-21, 2005. The first presentation highlighted data from a retrospective study conducted in tumour samples from patients of soft tissue sarcoma treated with Yondelis(R) in ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - New hope for HIV/AIDS patients: APTIVUS(R) outperforms several commonly prescribed drugs in the protease inhibitor (PI) class DUBLIN, Ireland, November 21 /PRNewswire/ -- - Experts Emphasize Need for Effective Therapy in Response to Increased Prevalence of HIV/AIDS throughout Europe At the 10th European AIDS Clinical Society (EACS) conference, experts ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - Additional Data Provide Further Guidance on Maximizing Treatment Response with APTIVUS(R) New data presented at the 10th European AIDS Conference (EACS) in Dublin demonstrate that through 48 weeks, APTIVUS(R) (tipranavir) provides a convincing and durable benefit, achieving and maintaining a superior treatment response in patients with resistant HIV.(1) ...
Dublin, Ireland, November 18 (ots/PRNewswire) - - Latest Advances in Health Psychology may Help Physicians Implement Improved HIV Care - News From 10th European AIDS Conference, Dublin, Ireland Initial results from the OpenMind study, the largest behavioural study to look at both patients' and ...
Lund, Switzerland, November 17 (ots/PRNewswire) - For Non-US Medical Journalists Only A new report on the importance of treating Chronic Obstructive Pulmonary Disease (COPD) exacerbations is launched today, on World COPD Day. Global dissemination of the report to family physicians/General Practitioners around the world is being supported and facilitated by ...
San Diego, California, November 17 (ots/PRNewswire) - - First Phase III Data Presented at the ACR Annual Meeting Roche today announced the results of the first Phase III study in rheumatoid arthritis (RA) conducted by Chugai in Japan which are being presented at the American College of Rheumatology (ACR) ...
Alderley Park, England, November 16 (ots/PRNewswire) - - New Data Add Momentum to AstraZeneca's Novel Oncology Drug, ZD6474 (ZACTIMA[TM]), Which has Already Shown Promising Data in Non-Small Cell Lung Cancer (NSCLC) Preliminary results from a Phase II study showing promising clinical data with ZD6474 ...
London, November 16 (ots/PRNewswire) - - For Non-US Media Only - PROactive Study Also Shows a 37 Percent Reduction in Acute Coronary Syndrome With ACTOS New results from secondary analyses of the landmark PROactive Study found that ACTOS(R) (pioglitazone) significantly reduced the occurrence of fatal ...
Edmonton, Canada, November 16 (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA), a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics, announced today that effective immediately, Joseph Koziak, who served as Executive Vice President is no longer an officer of the company. About Isotechnika Isotechnika Inc. is an international biopharmaceutical ...
Paris, November 16 (ots/PRNewswire) - - Emea Approves New Treatment for Chronic Stable Angina Procoralan (ivabradine, Servier), the first selective and specific If inhibitor, has received marketing authorization in 27 European countries from the European Medicines Evaluation Agency (EMEA) for the ...
Macclesfield, England, November 15 (ots/PRNewswire) - - For Health Professional Press Only - For International Journalists Only - Not for US Media - Retrospective ISEL Study Analysis Identifies Potential Indicator of Response to Treatment With gefitinib in Advanced NSCLC patients Data presented ...
Dallas, Texas, November 14 (ots/PRNewswire) - - FIELD Confirms Fenofibrate Produces Macrovascular and Microvascular Benefits in Diabetic Patients Without Previous Cardiovascular Disease Although Primary Endpoint is not met Results of the largest intervention study ever conducted for the prevention of ...
Dallas, Texas, November 14 (ots/PRNewswire) - - CAFÉ Study Shows Central Aortic Pulse Pressure Important Determinant of Cardiovascular Outcomes A new sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)(1), presented during a late breaking clinical trial session of the American Heart ...